Galderma Group AG/ADR

Overview

Compare with another stock.

• TickerGALDY on OTC¹
• HeadquartersNew York, New York¹
• Incorporated inSwitzerland²
• Business address383 Madison Avenue, Floor 11, New York, Ny 10179²

See how the biggest companies compare on our leaderboards

Calendar

Drug trials and FDA: coming up

1. Oct 26, 2026Phase 3 trial readout expected Phase 3 trial of Nemolizumab in Prurigo Nodularis: primary completion expected Oct 26, 2026 (ClinicalTrials.gov NCT04204616).³
2. Dec 31, 2026Phase 3 trial readout expected Phase 3 trial of Trifarotene and Vehicle Cream in Acne Vulgaris: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT07186413).⁴
3. Dec 2026Phase 2 trial readout expected Phase 2 trial of nemolizumab in Chronic Pruritus of Unknown Origin: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07074977).⁵

Drug trials and FDA: recently

1. Aug 31, 2026Phase 3 trial completed Phase 3 trial of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: primary completion Aug 31, 2026, no results posted yet (ClinicalTrials.gov NCT03989206).⁶
2. May 22, 2026FDA approval FDA approved Differin Epiduo Acne Gel (Adapalene And Benzoyl Peroxide) (adapalene, benzoyl peroxide) (NDA 220736).⁷
3. Apr 28, 2025Phase 2 trial completed Phase 2 trial of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: primary completion Apr 28, 2025, results posted May 26, 2026 (ClinicalTrials.gov NCT04921345).⁸
4. Dec 13, 2024FDA approval FDA approved Nemluvio (nemolizumab-ilto), a new molecular entity (BLA 761391).⁹
5. Aug 12, 2024FDA approval FDA approved Nemluvio (nemolizumab-ilto), a new molecular entity, priority review (BLA 761390).¹⁰
6. Mar 31, 2023Phase 3 trial completed Phase 3 trial of QM1114-DP in Glabellar Frown Lines: primary completion Mar 31, 2023, results posted May 29, 2026 (ClinicalTrials.gov NCT05148000).¹¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

3 filings to the SEC since October 2021: 3 other. The latest 3:

1. Sep 18, 2025F-6EF EDGAR
2. Apr 11, 2025F-6EF EDGAR
3. Apr 26, 2024F-6EF EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Galderma Group AG/ADR is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARGalderma Group AG/ADR¹
• CIK0002021390
• Incorporated inSwitzerland¹
• Fiscal year endsDecember 31¹
• SEC reviewing officeOffice of International Corp Fin, Division of Corporation Finance¹
• Business address383 Madison Avenue, Floor 11, New York, NY 10179¹
• Phone302-552-0866¹
• On EDGAR sinceApr 26, 2024¹
• Filings4 in all: F-6EF (4)¹